Preclinical Evidence for the Glucocorticoid-Sparing Potential of a Dual Toll-Like Receptor 7/8 Inhibitor in Autoimmune Diseases

J Pharmacol Exp Ther. 2023 doi: 10.1124/jpet.123.001744 Epub ahead of print

Preclinical evidence indicates a glucocorticoid (GC)-sparing potential for toll-like receptor (TLR)7/8 inhibitor compounds, suggesting TLR7/8i may offer a new strategy for the treatment of autoimmune diseases.

Despite being part of the standard of care for multiple immune disease, and their effectiveness, a plethora of undesirable effects limit the use of GCs. As such, new treatment approaches that allow for the use of lower and safer doses of GCs would be highly beneficial.

In this translational work, Deshmukh, et al. examine whether use of GCs and TLR7/8i in combination can synergistically reduce inflammation and autoimmunity.